Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Generic Coregs are coming
The FDA gave its blessing to more than a dozen generic versions of GlaxoSmithKline's Coreg (aka carvedilol), used to treat a variety of cardiovascular problems including high blood pressure and heart failure. Now, Glaxo will have to share the $1.7 billion carvedilol market with the likes of Actavis, Apotex, Caraco, Dr. Reddy's, Ranbaxy, Sandoz, Teva, and Watson, among others. A total of 14 generics were approved.
Ironically, the generic labeling may differ from the brand-name version because, while the drug itself is no longer under patent, certain bits of the labeling are.
- see the FDA release
Related Articles:
Riled investors look for big changes at GSK. Report
Patent 'cliff' looms for Big Pharma. Report
Be the first to comment
More stories about Teva Pharmaceutical Ranbaxy Patent GlaxoSmithKline Generics FDA approval FDA Coreg
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
